Free Republic

A nasal vaccine that could finally curb Covid infections is one step closer to a reality after promising early trial results. The inhaled vaccine, made by researchers in Georgia, successfully reduced the risk of symptomatic Covid infections by 86 percent for three months in people who received it as a booster - almost double the protection the mRNA boosters provide. While still in early stages, it is an exciting development that could prove more effective than the booster doses administered as injections. The nasal, or ‘mucosal’ vaccines are appealing for their ability to prime immune cells in the mucous membranes...

Antiviral Nasal Spray A single inhaled dose treated or even prevented infection by COVID-19 and its variants. Current antibody treatments block SARS-CoV-2 by binding to one of three binding sites on the spike protein New antiviral binds to all three sites on the spike protein, making it more effective than current therapies Antiviral is also low-cost, easy to manufacture, does not require complicated supply chains with extreme refrigeration and potentially could be self-administered A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Louis is being advanced toward Phase I...

A new experimental nasal spray could prevent people from getting infected with COVID-19 for up to eight hours, according to a study. The promising treatment has shown it can block infection from the virus in lab studies with mice, according to researchers at the University of Helsinki in Finland.

Dr. Peter McCullough is an internist, cardiologist, epidemiologist, a full professor of medicine at Texas A&M College of Medicine in Dallas, USA. He also has a master's degree in public health and is known for being one of the top five most-published medical researchers in the United States and is the editor of two medical journals.McCullough et al. Reviews in Cardiovascular Medicine, 2020McCullough et al. 2020In this Sept 14, 2021 interview with Peter Breggin MD, author of Talking Back to Prozac, Dr. Peter McCullough discusses the routine use of diluted (1%) Povidone Iodine mouth wash in the dental office as...

Last week, the World Tribune published an article revealing information that indicates the WHO likely knew ivermectin was effective for months, but blocked its use, all for Big Pharma. Dr. Andrew Hill, a senior visiting research fellow in pharmacology at Liverpool University, adviser to the Gates Foundation, and researcher for the WHO, was tasked with conducting an ivermectin trial for the WHO. Based on his preliminary findings, Hill testified enthusiastically about the use of ivermectin before the NIH COVID-19 Treatment Guidelines Panel on Jan. 6, 2021. But then he suddenly changed course and published a study dinging the drug’s efficacy...

Sen. Ron Johnson (R-Wis.) on Wednesday suggested that standard mouthwash could treat COVID-19, and criticized federal agencies for telling people to "do nothing." "Standard gargle, mouthwash, has been proven to kill the coronavirus," Johnson said, according to The Washington Post. "If you get it, you may reduce viral replication. Why not try all these things?" "It just boggles my mind that the NIH continues to tell people to do nothing," he added of the National Institutes of Health, in a recording posted online by Heartland Signal. The mouthwash strategy has been refuted by both health experts and mouthwash brands themselves....

Imagine reducing your viral load of COVID and decreasing your chance of hospitalization 19-fold with a $15 solution. Well, the corporate media have gotten wind of it too, which is why they are now attacking the nasal irrigation concoctions, proving once again that they will slander every and any treatment that actually works – no matter how safe and effective.It is now becoming clear that not only do the vaccines not stop transmission, but they seem to have spawned even more transmission in the most vaccinated countries. Studies have shown that the vaccinated might also carry higher viral loads. Either...

The leading U.S. manufacturer of xylitol-based products says the federal government is deliberately trying to conceal a nasal spray it developed that it says has been scientifically proven to be effective in treating and preventing COVID-19. The U.S. Department of Justice filed a lawsuit in federal court against Utah-based company Xlear on Oct. 28, saying it has deceptively advertised its nasal spray as a treatment and preventative of COVID-19. The lawsuit asks a federal court to permanently ban the company from promoting the nasal spray as a treatment for COVID-19 and also asks that monetary penalties be levied against it....

Nathan Jones, CEO of Xlear, said that he feels that his company is emerging from the COVID-19 pandemic in better shape and is prepared to help retailers in the post-COVID era. He talked with Drug Store News about the challenges ahead. Drug Store News: How has Xlear fared during the pandemic? Nathan Jones: Xlear as a company has fared fairly well. It is a respiratory pandemic and, within a month of it starting, we had physicians around the world tell people that using nasal sprays like ours, nasal sprays that contain antiviral agents, would be of benefit to them. There...

Enovid, a spray developed in Canada by SaNOtize and manufactured in Israel has been found to reduce viral loads in confirmed COVID-19 cases by 95% in 24 hours and 99% in 72 hours. The anti-viral nasal spray called Enovid that was developed in Canada and tested in the UK can reduce the viral loads in confirmed COVID-19 cases by 95% in 24 hours and 99% in 72 hours, a press release said on Sunday. *The Israeli-manufactured spray can be used up to five times a day after coming in contact with viruses, according to the release. It's suitable for children...

Randomized, double-blind, placebo-controlled trial evaluated 79 confirmed cases of COVID-19, the majority heavily-infected with the UK variant.ADVERTISEMENTPatients with a self-administered nasal spray application found to have reduced SARS-CoV-2 log viral load by more than 95% in infected participants within 24 hours of treatment, and by more than 99% in 72 hoursTrial concluded that treatment accelerated clearance of SARS-CoV-2 by a factor of 16-fold versus a placeboRandomized, double-blind, placebo-controlled trial evaluated 79 confirmed cases of COVID-19, the majority heavily-infected with the UK variantNo adverse events were recorded in the groupSubmission for Emergency Use in the UK and Canada for the treatment...

As nations around the globe race to find different solutions to prevent the further spread of the dreaded COVID-19 virus, Israel gave interim approval for the sale of Canadian-based biotech company SaNOtize Research and Development’s Nitric Oxide Nasal Spray (NONS) branded as Enovid. SaNOtize developed and patented the platform technology that allows for the topical delivery of Nitric Oxide (the formula written as NO) for treating a variety of bacterial, fungal, and viral diseases. Utilizing the unique antimicrobial and immunomodulating properties of NO to treat both dermatologic and respiratory diseases, the production of this nose spray that claims to kill...

WASHINGTON--(BUSINESS WIRE)- Xlear has filed a Pre-Emergency Use Authorization (Pre-EUA) Request with the U.S. Food and Drug Administration (FDA) seeking approval to make claims that the nasal spray is approved for use in preventing SARS-CoV-2 (COVID-19) transmission and infection. The Pre-EUA is a first step in seeking formal authorization of Xlear Nasal Spray as tool to help in combatting COVID-19. Xlear previously filed a pre-EUA seeking approval for use of the nasal spray as a medical device in combatting COVID-19. However, because the FDA determined that Xlear “works against the virus,” the FDA told Xlear it would need to be...

ERUSALEM, March 22 (Reuters) - Israel and New Zealand have given interim approval for the sale of biotech firm SaNOtize Research and Development's Nitric Oxide Nasal Spray (NONS) which could help prevent transmission of the COVID-19 virus, the company said on Monday. Manufacturing of NONS, under the brand name Enovid, has begun in Israel with SaNOtize's partner Nextar Chempharma Solutions Ltd and it is expected to be on sale there this summer. In New Zealand, SaNOtize has registered its nasal spray with the New Zealand Medicines and Medical Devices Safety Authority, which permits the company to distribute and sell NONS...

Gilly Regev says her 'hand sanitiser for the nose' is inexpensive and can be distributed to poorer countries to stop the spread of the virusThe Israeli co-founder of a nasal spray that kills 99.9% of the coronavirus that causes Covid-19, has told Jewish News that she believes the spray will be a game changer in the fight against Covid-19. Dr Gilly Regev, who co-founded SaNOtize Research and Development Corp. based in Vancouver, Canada explained via telephone that “If you use it daily, I really believe you won’t be affected by Covid-19. We have shown in the clinical trials that the...

Dr Gilly Regev, who co-founded SaNOtize Research and Development Corp, speaking during a promotional video for its nasal sprayThe Israeli co-founder of a nasal spray that kills 99.9% of the coronavirus that causes Covid-19, has told Jewish News that she believes the spray will be a game changer in the fight against Covid-19. Dr Gilly Regev, who co-founded SaNOtize Research and Development Corp. based in Vancouver, Canada explained via telephone that “If you use it daily, I really believe you won’t be affected by Covid-19. We have shown in the clinical trials that the people who used it did not...

A commercially available nasal antiseptic solution "inactivates" COVID-19 just 15 seconds after the coronavirus is exposed to it, effectively preventing the infection from developing, according to a study published Thursday by JAMA Otolaryngology-Head & Neck Surgery. By inactivating the virus, the antiseptic nasal rinse -- a povidone-iodine solution administered in the nostril -- also would help prevent those infected from spreading it to others, the researchers said. The findings are based on lab experiments designed to assess how the rinse affects new coronavirus cells "in vitro," or in test tubes. Researchers have yet to study the rinse in humans with...

Spravato is a nasal spray administered by an approved health care provider in a doctor's office or a medical clinic. It may also be self-administered but only under the supervision of a care provider and cannot be taken home. "Because of [safety] concerns, the drug will only be available through a restricted distribution system and it must be administered in a certified medical office where the health care provider can monitor the patient," Farchione said. Depending on the severity of the patient's depression, it is given either once a week or once every other week. n. The drug is rapidly...

(AP) Health officials say the first doses of swine flu vaccine will be the nasal spray version. The Centers for Disease Control and Prevention said Friday that about 3.4 million doses of nasal spray vaccine will be available the first week of October. The government expects 195 million doses will be shipped out by the end of the year, most of them shots. The nasal spray is approved for ages 2 to 49. It's not recommended for some of the people at most risk from severe swine flu complications. That includes pregnant women, children younger than 2, and people with...

WASHINGTON (Reuters) - The first roll-out of vaccines against the new swine flu virus will be 3.4 million doses of MedImmune's needle-free nose spray, the U.S. Centers for Disease Control and Prevention said on Friday. The CDC's Dr Jay Butler said the vaccines would be distributed the first week of October. "Initially we anticipate that 3.4 million doses of vaccine will be available," Butler told a telephone briefing. "We estimate that the amount of vaccine that will be available will increase through October." He said eventually delivery would rise to about 20 million doses a week. The United States has...